T. Rowe Price Associates
ZYME icon

T. Rowe Price Associates’s Zymeworks ZYME Stock Holding History

T. Rowe Price Associates’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
38,486
+2,999
+8% +$76.2K ﹤0.01% 2333
2026
Q1 		$889K Buy
35,487
+6,703
+23% +$159K ﹤0.01% 2212
2025
Q4 		$758K Buy
28,784
+1,968
+7% +$42.9K ﹤0.01% 2206
2025
Q3 		$459K Hold
26,816
– – ﹤0.01% 2392
2025
Q2 		$337K Buy
26,816
+2,703
+11% +$32.2K ﹤0.01% 2481
2025
Q1 		$288K Buy
24,113
+2,530
+12% +$34.5K ﹤0.01% 2488
2024
Q4 		$316K Buy
21,583
+3,235
+18% +$45.2K ﹤0.01% 2486
2024
Q3 		$231K Buy
18,348
+1,279
+7% +$13.9K ﹤0.01% 2598
2024
Q2 		$146K Buy
17,069
+1,405
+9% +$12.5K ﹤0.01% 2671
2024
Q1 		$165K Buy
15,664
+2,351
+18% +$26.1K ﹤0.01% 2675
2023
Q4 		$139K Buy
13,313
+1,752
+15% +$14K ﹤0.01% 2650
2023
Q3 		$74K Buy
11,561
+739
+7% +$5.46K ﹤0.01% 2716
2023
Q2 		$94K Buy
+10,822
New +$96.9K ﹤0.01% 2709
2022
Q1 		– Sell
-1,714,905
Closed -$28.1M – 3025
2021
Q4 		$28.1M Buy
1,714,905
+17,592
+1% +$367K ﹤0.01% 1196
2021
Q3 		$49.3M Buy
1,697,313
+647,666
+62% +$21.5M ﹤0.01% 1015
2021
Q2 		$36.4M Sell
1,049,647
-136,150
-11% -$4.32M ﹤0.01% 1136
2021
Q1 		$37.4M Sell
1,185,797
-5,062
-0.4% -$206K ﹤0.01% 1100
2020
Q4 		$56.3M Buy
1,190,859
+71,443
+6% +$3.32M 0.01% 921
2020
Q3 		$52.1M Sell
1,119,416
-96,006
-8% -$3.3M 0.01% 856
2020
Q2 		$43.8M Buy
1,215,422
+255,016
+27% +$9.39M 0.01% 890
2020
Q1 		$34.1M Buy
960,406
+85,843
+10% +$3.51M 0.01% 908
2019
Q4 		$39.8M Buy
874,563
+222,547
+34% +$8.09M 0.01% 988
2019
Q3 		$16.2M Buy
652,016
+348,595
+115% +$8.73M ﹤0.01% 1211
2019
Q2 		$6.67M Buy
+303,421
New +$5.57M ﹤0.01% 1362

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

T. Rowe Price Associates's ZYME Position: Q2 2026 in Review

T. Rowe Price Associates increased its Zymeworks (ZYME) stake by 8.5% in Q2 2026, buying an estimated $76.2K and bringing the position to 38,486 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

T. Rowe Price Associates first reported a position in ZYME in Q2 2019 and has held it in 24 quarters since. The position peaked at $56.3M in Q4 2020. 202 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

  • T. Rowe Price Associates held 38,486 shares of Zymeworks worth $1.01M as of Q2 2026.
  • T. Rowe Price Associates bought 2,999 Zymeworks shares in Q2 2026, an estimated $76.2K.
  • Zymeworks made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2333 holding.
  • T. Rowe Price Associates first reported a position in Zymeworks in Q2 2019 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Zymeworks position peaked at $56.3M in Q4 2020.
  • 202 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.